Physician profile
Douglas J Mclaughlin
NPI 1023075413
$160,547.53
in general payments reported to CMS, 2019-2025
16 companies · $36K in 2025
The $36K reported for 2025 was more than what 97% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,450 · 2020: $2,357 · 2021: $8,999 · 2022: $24K · 2023: $57K · 2024: $24K · 2025: $36K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $53K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $37K · Honoraria: $17K · Travel and Lodging: $7,424 · Food and Beverage: $3,655.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $52,503.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $36,797.00 |
| Honoraria | $16,775.00 |
| Travel and Lodging | $7,424.10 |
| Food and Beverage | $3,655.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $62,278.50 | 2022-2025 | Auvelity |
| Abbvie INC. | $36,994.70 | 2021-2024 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $14,443.69 | 2019-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $12,662.22 | 2019-2023 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $11,454.54 | 2024-2025 | Cobenfy |
| Allergan, INC. | $9,914.06 | 2019-2020 | |
| Alkermes, INC. | $8,592.03 | 2019-2024 | Lybalvi |
| Teva Pharmaceuticals USA, INC. | $3,337.05 | 2019-2023 | Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $384.52 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $220.29 | 2019-2022 | |
| Lundbeck LLC | $180.04 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $29.69 | 2019 | |
| Eisai INC. | $15.43 | 2021 | |
| Supernus Pharmaceuticals, INC. | $14.99 | 2025 | Qelbree |
| Shire North American Group INC | $14.95 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $10.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Mclaughlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.